The big shareholder groups in Savara Inc. (NASDAQ:SVRA) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often ...

As of December 6, 2025, the average one-year price target for Savara is $10.52/share. The forecasts range from a low of $7.07 to a high of $16.80. The average price target represents an increase of 73 ...

Investors might want to bet on Savara Inc (SVRA), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the ...

The latest trial study from Savara Inc (NASDAQ:SVRA) met its primary endpoint. The company released results from Phase 3 IMPALA-2 trial of molgramostim 300 mcg administered once daily by inhalation ...

Savara Inc. (NASDAQ:SVRA) on Tuesday announced that it received a U.S. Food And Drug Administration (FDA) refusal To File (RTF)) letter regarding the Biologic license application (BLA) for Molbreevi, ...

Savara Inc. recently reported that the European Patent Office intends to grant a patent covering the liquid formulation of MOLBREEVI, its orally inhaled recombinant human GM-CSF for treating ...

I arrived early to High Plains Raceway, a racetrack about an hour's drive from Denver. It was going to be a long day and I was clinging tightly to my hot tea as I wandered about the paddock in the ...

Three short years ago, SVRA, one of the industry's oldest vintage racing organizations, was predominantly a regional South East organization with approximately 500 members who participated in 5 races ...

Fintel reports that on December 18, 2025, Wells Fargo maintained coverage of Savara (NasdaqGS:SVRA) with a Overweight ...